MedinCell S.A. (LON:0ACH)

Market Cap	465.60M
Revenue (ttm)	23.20M
Net Income (ttm)	-15.42M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	79.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141
Average Volume	817
Open	16.23
Previous Close	16.22
Day's Range	16.18 - 16.23
52-Week Range	12.02 - 18.78
Beta	1.08
RSI	46.65
Earnings Date	Jun 17, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 140
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ACH

Financial Performance

In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.

Financial numbers in EUR